INSMED (NASDAQ: INSM) CEO exercises options and sells 10,699 shares under 10b5-1 plan
Rhea-AI Filing Summary
INSMED Inc Chair and CEO William Lewis exercised stock options and sold shares in a planned transaction. On 2026-03-19, he exercised options for 10,699 shares of common stock at exercise prices of $30.46 and $17.16 per share, converting them into common shares.
That same day, he sold 10,699 shares of common stock in open-market trades at weighted average prices ranging from about $141.80 to $144.72, under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025. After these transactions, he directly holds 301,185 shares, plus 233,924 shares held indirectly through the Katie Procter Dynasty Trust.
Positive
- None.
Negative
- None.
Insights
Routine option exercise paired with 10b5-1 sales; position remains sizable.
Chair and CEO William Lewis exercised options for 10,699 shares of INSMED Inc common stock at exercise prices of $30.46 and $17.16 per share, then sold an equal number of shares in open-market trades.
The filing notes these sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025, which typically indicates a scheduled, portfolio-management process rather than discretionary timing. Following the net-sell activity, he still directly holds 301,185 shares and indirectly 233,924 through the Katie Procter Dynasty Trust.
This pattern is characteristic of an exercise-and-sell sequence where options are converted into shares and then monetized, while a substantial equity stake is retained. From an investment perspective, such 10b5-1 activity is generally interpreted as routine and not thesis-changing absent additional company-specific developments.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 6,259 | $0.00 | -- |
| Exercise | Stock Option (right to buy) | 4,440 | $0.00 | -- |
| Exercise | Common Stock | 6,259 | $30.46 | $191K |
| Exercise | Common Stock | 4,440 | $17.16 | $76K |
| Sale | Common Stock | 1,629 | $142.17 | $232K |
| Sale | Common Stock | 4,537 | $143.42 | $651K |
| Sale | Common Stock | 4,533 | $144.11 | $653K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This is the weighted average sales price representing 1,629 shares sold at prices ranging from $141.80 to $142.74 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 4,537 shares sold at prices ranging from $142.80 to $143.77 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 4,533 shares sold at prices ranging from $143.80 to $144.72 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
